These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Bok RA; Halabi S; Fei DT; Rodriquez CR; Hayes DF; Vogelzang NJ; Kantoff P; Shuman MA; Small EJ Cancer Res; 2001 Mar; 61(6):2533-6. PubMed ID: 11289126 [TBL] [Abstract][Full Text] [Related]
6. Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression. Kurschat P; Eming S; Nashan D; Krieg T; Mauch C Br J Dermatol; 2007 Apr; 156(4):653-8. PubMed ID: 17263813 [TBL] [Abstract][Full Text] [Related]
7. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762 [TBL] [Abstract][Full Text] [Related]
8. [Treatment of advanced Wilms' tumor]. Li MJ; Huang Y; Tang DX; Zhou YB; Tang HF; Liang JF Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):791-5. PubMed ID: 17366799 [TBL] [Abstract][Full Text] [Related]
10. High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer. Ruotsalainen T; Joensuu H; Mattson K; Salven P Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1492-5. PubMed ID: 12433733 [TBL] [Abstract][Full Text] [Related]
11. Serum bFGF (basic fibroblast growth factor) and CA 15.3 in the monitoring of breast cancer patients. Pichon MF; Moulin G; Pallud C; Pecking A; Floiras JL Anticancer Res; 2000; 20(2B):1189-94. PubMed ID: 10810420 [TBL] [Abstract][Full Text] [Related]
12. Urinary basic fibroblast growth factor in bladder cancer patients. Histopathological correlation and clinical potential. Gravas S; Bosinakou I; Kehayas P; Giannopoulos A Urol Int; 2004; 73(2):173-7. PubMed ID: 15331904 [TBL] [Abstract][Full Text] [Related]
13. Wilms' tumor at the Children's Hospital of Eastern Ontario: 1990-2001. Pianezza ML; Rubin S; Bass J; Chou S; Pike JG; Leonard MP Can J Urol; 2004 Feb; 11(1):2151-6. PubMed ID: 15003157 [TBL] [Abstract][Full Text] [Related]
14. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222 [TBL] [Abstract][Full Text] [Related]
15. [Risk factors for perioperative complications in renal surgery for Wilms' tumor]. Seseke F; Rebmann S; Zöller G; Lakomek M; Ringert RH Aktuelle Urol; 2007 Jan; 38(1):46-51. PubMed ID: 17290329 [TBL] [Abstract][Full Text] [Related]
16. Quality assessment for Wilms' tumor: a report from the National Wilms' Tumor Study-5. Ehrlich PF; Ritchey ML; Hamilton TE; Haase GM; Ou S; Breslow N; Grundy P; Green D; Norkool P; Becker J; Shamberger RC J Pediatr Surg; 2005 Jan; 40(1):208-12; discussion 212-3. PubMed ID: 15868587 [TBL] [Abstract][Full Text] [Related]
17. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Aguayo A; Kantarjian HM; Estey EH; Giles FJ; Verstovsek S; Manshouri T; Gidel C; O'Brien S; Keating MJ; Albitar M Cancer; 2002 Nov; 95(9):1923-30. PubMed ID: 12404286 [TBL] [Abstract][Full Text] [Related]
18. The prognostic relevance of preoperative transcatheter arterial chemoembolization (TACE) and PCNA/VEGF expression in patients with Wilms' tumour. Liu WG; Gu WZ; Zhou YB; Tang HF; Li MJ; Ma WX Eur J Clin Invest; 2008 Dec; 38(12):931-8. PubMed ID: 19021718 [TBL] [Abstract][Full Text] [Related]
20. Differential expression of the drug resistance markers DNA topoisomerase II alpha and glutathione S-transferase-pi in the histological compartments of Wilms' tumors. Granzen B; Efferth T; Keller U; Beniers AJ; Mertens R; Jakse G; Füzesi L Anticancer Res; 2001; 21(1B):771-6. PubMed ID: 11299842 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]